ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,793Medicare Part D Prescriptions Filled, Including Refills

Rank: 272 out of 780

$561K Total Retail Price of All Prescriptions

Rank: 258 out of 780

513 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
40% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 513 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 513 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

2% of this provider’s 8,265 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 23.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
AMLODIPINE BESYLATE 554 467 1 4
LEVOTHYROXINE SODIUM 550 465 2 5
HYDROCODONE-ACETAMINOPHEN 398 267 S3 3 1
OMEPRAZOLE 388 299 4 3
SIMVASTATIN 343 266 5 2
LISINOPRIL 320 214 6 6
FUROSEMIDE 228 196 7 7
MELOXICAM 222 164 8 16
PRAVASTATIN SODIUM 207 193 9 9
METFORMIN HCL ER 199 127 10 43
METFORMIN HCL 178 121 11 8
LOSARTAN POTASSIUM 156 122 12 18
METOPROLOL SUCCINATE 147 116 13 20
ATORVASTATIN CALCIUM 141 99 14 12
HYDROCHLOROTHIAZIDE 135 106 15 10
CITALOPRAM HBR 131 112 16 23
AMLODIPINE BESYLATE-BENAZEPRIL 129 88 17 50
PANTOPRAZOLE SODIUM 126 101 18 25
NEXIUM 117 66 19 22
SERTRALINE HCL 115 92 20 27
TRIAMTERENE-HCTZ 113 99 21 37
ZOLPIDEM TARTRATE 109 71 22 17
POTASSIUM CHLORIDE 107 72 23 11
GABAPENTIN 107 66 23 13
TRAMADOL HCL 104 92 25 15
LOSARTAN-HYDROCHLOROTHIAZIDE 103 82 26 33
CLONIDINE HCL 103 65 26 28
LISINOPRIL-HYDROCHLOROTHIAZIDE 95 89 28 26
LOVASTATIN 94 94 29 47
CYMBALTA 92 53 30 51
ATENOLOL 90 63 31 21
ALENDRONATE SODIUM 89 89 32 44
DIOVAN 80 80 33 55
CRESTOR 78 61 34 32
DONEPEZIL HCL 76 74 35 31
CYCLOBENZAPRINE HCL 75 27 R 36 42
CARVEDILOL 74 65 37 14
KLOR-CON 10 70 60 38 90
NAMENDA 70 70 38 46
ZETIA 67 51 40 94
METOPROLOL TARTRATE 65 51 41 19
KLOR-CON M20 65 50 41 57
VESICARE 61 61 43 186
ISOSORBIDE MONONITRATE ER 61 48 43 60
BISOPROLOL-HYDROCHLOROTHIAZIDE 61 61 43 95
JANUVIA 60 53 46 85
ESCITALOPRAM OXALATE 58 44 47 61
CIPROFLOXACIN HCL 57 46 48 49
GLIMEPIRIDE 54 23 49 30
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 2, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.